deltatrials
Completed PHASE1/PHASE2 NCT00426855

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

Weekly Bendamustine and Bortezomib Combination Therapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or B-CLL: A Single-Center Phase 2 Study

Sponsor: Kantonsspital Aarau

Conditions Lymphoma, Non-Hodgkin
Interventions Bendamustine Bortezomib
Updated 7 times since 2017 Last updated: Apr 2, 2015 Started: Jan 31, 2007 Primary completion: Feb 28, 2009 Completion: Jun 30, 2009

This PHASE1/PHASE2 trial investigates Lymphoma, Non-Hodgkin and is currently completed. Kantonsspital Aarau leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kantonsspital Aarau
  • Peter Moosmann
Data source: Kantonsspital Aarau

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.